Collegium Pharma’s EVP‑GC Sells 14,000 Shares Amid $650 Million AZSTARYS Deal, No Market Shock Expected
Collegium’s $650 M AZSTARYS acquisition sparks modest insider selling, yet signals confidence in future earnings growth and strategic cross‑selling potential.
- Collegium Pharmaceutical Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
